Improving decision making on DPYD and UGT1A1*28 patients' profiling with an innovative reimbursement strategy

Rossana Roncato; Erika Cecchin; Giuseppe Toffoli

doi:10.2217/pgs-2017-0303

Improving decision making on DPYD and UGT1A1*28 patients' profiling with an innovative reimbursement strategy

Pharmacogenomics. 2018 Mar;19(4):301-304. doi: 10.2217/pgs-2017-0303. Epub 2018 Feb 14.

Authors

Rossana Roncato¹, Erika Cecchin¹, Giuseppe Toffoli¹

Affiliation

¹ Experimental & Clinical Pharmacology, Centro Di Riferimento Oncologico - National Cancer Center, Aviano (PN), Italy.

PMID: 29441806
DOI: 10.2217/pgs-2017-0303

No abstract available

Keywords: DRG; cost of toxicity management; direct medical costs; personalized medicine; pharmacoeconomy; pharmacogenomics; real-world data; reimbursement strategy.

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Decision Making
Genotype
Glucuronosyltransferase / genetics*
Humans
Pharmacogenetics / methods
Precision Medicine / methods

Substances

UGT1A1 enzyme
Glucuronosyltransferase